Neovascular age-related macular degeneration (AMD) has undergone substantial break-
throughs in diagnostic as well as therapeutic respect, with optical coherence tomography …

Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become
a standard treatment for neovascular age‐related macular degeneration (AMD). During this …

PURPOSE: To describe the usage patterns of pharmacological treatments for neovascular
age-related macular degeneration (AMD) in Medicare fee-for-service beneficiaries. DESIGN …

The use of anti-vascular endothelial growth factor (VEGF) agents has profoundly changed
the prognosis of neovascular age-related macular degeneration (nAMD). As clinical …

Despite the success of antiangiogenic therapy in controlling exudation in neovascular age-
related macular degeneration (nAMD), the involvement of the outer retina in fibrosis results …

Ocular and systemic safety of bevacizumab and ranibizumab in... : Current Opinion in
Ophthalmology Ocular and systemic safety of bevacizumab and ranibizumab in patients with …

Individualized treatment regimens may reduce patient burden with satisfactory patient
outcomes in neovascular age‐related macular degeneration. Intravitreal anti‐VEGF drugs …

Background The effects of intravitreal ranibizumab (IVR) against exudative age-related
macular degeneration (AMD) may be different associated with the lesion phenotype. This …

Introduction Intravitreal bevacizumab (IVTB) is used to treat age-related macular
degeneration (ARMD), although its use is off-label and its cardiovascular safety has not …

Objective: As the off-label use of intravitreal bevacizumab continues for an increasing
number of ocular conditions, a systematic review of the literature aimed at detecting …